X0206 3 2021-10-21 0 0001840233 Xilio Therapeutics, Inc. XLO 0001780602 SV7 Impact Medicine Fund LP 71 KINGSWAY LONDON X0 WC2B 6ST UNITED KINGDOM 0 0 1 0 0001889859 SV7 (IMF) GP LLP 71 KINGSWAY LONDON X0 WC2B 6ST UNITED KINGDOM 0 0 1 0 Series B Convertible Preferred Stock 0.00 Common Stock 998544 D Series B Convertible Preferred Stock 0.00 Common Stock 998544 I See footnote Series C Convertible Preferred Stock 0.00 Common Stock 302588 D Series C Convertible Preferred Stock 0.00 Common Stock 302588 I See footnote Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (together, the "Preferred Stock") will automatically convert into 0.1053 shares of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"). The Preferred Stock has no expiration date. Consists of shares of common stock underlying shares of convertible preferred stock held by SV7 Impact Medicine Fund LP, via its general partner SV7 (IMF) GP LLP. Catherine Bingham, Michael Ross, who is a member of our board of directors, and Houman Ashrafian are members of the investment committee of SV7 (IMF) GP LLP, which has voting and investment power with respect to these shares, and may be deemed to beneficially own such shares. SV7 (IMF) GP LLP and Ms. Bingham, Mr. Ross and Mr. Ashrafian each disclaim beneficial ownership of the shares held herein except to the extent of their pecuniary interest therein. The address of SV7 Impact Medicine Fund LP is 71 Kingsway, London, WC2B 6ST, United Kingdom. Exhibit 24.1: Power of Attorney (SV7 Impact Medicine Fund LP) Exhibit 24.2: Power of Attorney (SV7 (IMF) GP LLP) /s/ Kathleen R. Henry, pursuant to Power of Attorney for SV7 Impact Medicine Fund LP 2021-10-21 /s/ Kathleen R. Henry, pursuant to Power of Attorney for SV7 (IMF) GP LLP 2021-10-21